Sign up by: 31 December 2025
Nabilone is a drug that has been shown in previous studies to improve the symptoms of patients with moderate to severe Alzheimer's Disease (AD) including agitation in small studies, as well as cognition and caregiver distress, with minimal side effects - a stark contrast to existing and prospective treatments showing various drawbacks. The overall objective of this study is to assess the safety and efficacy of nabilone for managing agitation in patients with AD in large multi-center study and to identify biological markers for assessing agitation severity and treatment response. This study will also review whether Nabilone is beneficial for other outcomes, such as overall neuropsychiatric symptoms, caregiver distress, cognition, nutritional status, pain, and global function in patients with moderate-to-severe AD over 9 weeks.
Key Details
Study Sponsor: The regulatory sponsor for this study is Sunnybrook Research Institute (SRI), with their Centre for Clinical Trial Support (CCTS) being the coordinating centre for the study. The funding agencies supporting this study are the Alzheimer's Drug Discovery Foundation (ADDF), and the Weston Brain Institute (WBI).
Location: In-person (700 Gordon Street, Whitby, ON) and phone
How Often: intake of drug required daily
Compensation: You may be reimbursed for parking or transportation to the clinic.
Contact
Dr. Amer Burhan, Geriatric Psychiatrist
905-430-4055 Ext 6053